Another study reported that in 13 patients treated with first‐ or second‐generation EGFR–TKIs immediately after anti‐PD‐1 antibody failure, the response rate was 46.1%, with no grade 3/4 adverse events or ILD.4 Here, EGFR is linked to interstitial lung disease.